CN1173500A - 聚乙二醇－干扰素结合物 - Google Patents

聚乙二醇－干扰素结合物 Download PDF

Info

Publication number
CN1173500A
CN1173500A CN97105434A CN97105434A CN1173500A CN 1173500 A CN1173500 A CN 1173500A CN 97105434 A CN97105434 A CN 97105434A CN 97105434 A CN97105434 A CN 97105434A CN 1173500 A CN1173500 A CN 1173500A
Authority
CN
China
Prior art keywords
peg
interferon
protein
reagent
binding substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN97105434A
Other languages
English (en)
Other versions
CN1155618C (zh
Inventor
R·卡拉西韦茨
C·纳林
P·罗森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Setters
F Hoffmann La Roche AG
Original Assignee
Setters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Setters filed Critical Setters
Publication of CN1173500A publication Critical patent/CN1173500A/zh
Application granted granted Critical
Publication of CN1155618C publication Critical patent/CN1155618C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

本发明涉及具有生理活性的水溶性聚乙二醇同干扰素的结合物,以及可用来制备这些结合物的新型聚乙二醇化合物。

Description

聚乙二醇-干扰素结合物
本申请是申请号为93116479.6、申请日为1993年8月25日、发明名称为“聚乙二醇-干扰素结合物”的发明专利申请的分案申请。
许多天然的和重组的蛋白质都具有医疗和医药效用。一旦被纯化并制成制剂，它们能够对各种临床适应征进行非肠道使用。然而，非肠道使用的蛋白质可能具有免疫原性，可能相对来说不易溶于水，也可能药理半寿期短。结果，病人体内的蛋白质很难达到有效治疗的血液水平。
这些问题可通过将蛋白质同聚合物(如聚乙二醇)结合来克服。Davis等人在美国专利4,179,337中公开了将聚乙二醇(PEG)结合到蛋白质(如酶和胰岛素)上，从而得到其中蛋白质免疫原性较低，但能保持大部分生理活性的结合物。Nakagawa等人公开了将PEG结合到小岛活化蛋白质上以减少其副作用和免疫原性。Veronese等人在Applied Biochem.and Biotech，11：141-152(1985)上公开了用氯甲酸苯酯类来活化聚乙二醇以修饰核糖核酸酶和超氧化物歧化酶。Katre等人在美国专利4,766,106和4,917,888上也公开了通过聚合物结合使蛋白质增溶。将PEG和其它聚合物同重组蛋白质结合以减弱蛋白质的免疫原性和提高它们的半寿期。参见Nitecki等人的美国专利4,902,502；Enzon公司的国际申请PCT/US90/03133；Nishimura等人的欧洲专利申请154,316；Tomasi的国际申请PCT/US85/02572。
以往形成PEG/蛋白质结合物的方法以及由所述方法得到的结合物存在几个问题。其一是形成这些蛋白质-PEG结合物的某些方法可能使蛋白质失活，从而使得到的结合物的生物活性可能较差。另外，在形成这些PEG-蛋白质结合物时所用的某些连接剂可能易在体内水解断开。当给药以后发生这样的断裂时，这些结合物便失去了由PEG带来的有利性能。
本发明的一个实施方案是由独特的连接剂将干扰素(IFN)的氨基连接到PEG上的新型干扰素-PEG结合物。本发明特别涉及通式I的具有生物活性的干扰素结合物：
Figure A9710543400041
其中R为低级烷基；R1、R2、R3和R4为H或低级烷基；m选自≥1的整数到干扰素中可及的氨基的数目；W为O或NH；x为1-1000之间的整数，y和z为0-1000之间的整数，x、y和z三者之和为3-1000；
附带条件，R1、R2、R3和R4中至少有一个是低级烷基。
式I中的-NH-基团由干扰素分子中可及的氨基衍生而来的，这一点是不言而喻的。
更具体地说，两种不同的干扰素结合物具有下列化学式：
Figure A9710543400042
其中R为低级烷基；R1、R2、R3、R4为H或低级烷基；m为最大可到干扰素中可及氨基数的数字；x、y和z选自使结合物具有形成结合物的蛋白质的至少一部分生物活性的任意数字组合；附带条件是，R1、R2、R3和R4中至少有一个是低级烷基。
图1：用实施例7的化合物进行PEG修饰的时间进程。干扰素(5mg/ml)与相对于蛋白质过量10倍、20倍或40倍的试剂一起在25mMTricine(pH10.0)、0.5M KSCN、100mM NaCl中保温所示时间。在不同时刻取等分试样，用甘氨酸停止反应，在15％的SDS-PAGE凝胶上分析。标记“I”为干扰素。
图2：用实施例5的化合物进行PEG修饰的时间进程。象图1中那样，干扰素与过量3倍或10倍的试剂一起保温所示的时间。在所示时刻取等分试样，用甘氨酸停止反应，在15％SDS-PAGE凝胶上分析。“S”为蛋白质分子量标准物的标记，“I”为干扰素的标记。
图3：用实施例1(左侧)和实施例3(右侧)的化合物进行PEG修饰的比较。干扰素与3倍过量的试剂一起保温0.25、1.5或24小时。取出等分试样，用甘氨酸停止反应并在15％SDS-PAGE凝胶上分析。“S”为蛋白质分子量标准物的标记，“I”为干扰素的标记。
按照本发明，式IA和式IB的IFN结合物可如下制得：使末端羟基或氨基已被活化的连接基团取代的活化PEG缩合，然后，这些试剂可与IFN中的一个或更多个氨基反应。只同一个氨基缩合形成单PEG化的结合物是本发明的优选实施方案。所以，本发明也涉及那些可用来制备本发明的干扰素结合物的新型活化化合物(试剂)。这些化合物具有下列通式：
Figure A9710543400051
其中R为低级烷基；R1、R2、R3、R4和R5为H或低级烷基；W为NH或O；x为1-1000的整数，y和z为0-1000的整数，x、y和z三者之和为3-1000；附带条件是，假如W为NH或W为O，R5为H，则R1、R2、R3和R4中至少有一个为低级烷基；
Figure A9710543400061
其中，R为低级烷基；R1、R2、R3和R4为H或甲基；x为1-1000的整数，y和z为0-1000的整数，x、y和z三者之和为3-1000。
更具体地说，式II包括下列两种类型的化合物：
Figure A9710543400062
Figure A9710543400063
在IIA、IIB和III中，R、R1、R2、R3、R4和R5均如上所述；x、y和z选自能使聚合物在同蛋白质结合后允许蛋白质保持至少一部分结合前生物活性水平的任何数字组合；加上式II中所提到的附带条件。
按照本发明，通过使用式IIA、IIB或III的活化的PEG试剂制备结合物，在蛋白质(如干扰素(IFN))的游离氨基和PEG之间形成了一个连键，使所得的结合物保持了蛋白质的至少一部分生物活性，但免疫原性降低。另外，通过使用式IIA、IIB或III中的任何一种活化的聚乙二醇而在本发明结合物中形成的连接基团，使所得的蛋白质结合物不易在体内水解断开，也不易出现先有技术PEG蛋白质结合物中所存在的缺点。
按照本发明，R、R1、R2、R3、R4和R5可以是低级烷基，优选甲基。低级烷基指含1-6个碳原子的低级烷基，如甲基、乙基、正丙基、异丙基等。通常，优选的烷基是含1-4个碳原子的低级烷基，其中甲基是最优选的。R1、R2、R3、R4和R5也可以是氢，但R1、R2、R3和R4不能同时为氢。
按照本发明，x、y和z可以选自能使所得结合物保持形成结合物的IFN的至少一部分生物活性的任何数字组合。显然，x、y和z的总和以及m与结合物所保持的IFN生物活性量成反比。x、y和z的数值代表形成结合物的聚乙二醇中的二醇单元数。m代表IFN中包含的能与活化的PEG混合物反应的游离氨基或可及氨基数。m以及x、y和z的值越大，结合物的分子量越大。按照本发明，x、y和z是使除了蛋白质部分以外的结合物分子量在约300-30,000道尔顿的任何数字。对于IFN，m优选1-3。一个特别优选的实施方案是m为1的单PEG化的结合物，它的制备条件能够以高收率得到IFN中仅有一个游离氨基同式IIA或IIB或III的PEG试剂反应的IFN结合物。按照m为1的优选实施方案，x、y和z是使形成结合物的二醇的平均分子量为大约300-30,000道尔顿，优选大约1,000-10,000道尔顿，尤其是大约1,000-5,000道尔顿的任何数字。特别优选的实施方案是分子量大约为2,000道尔顿。
至于单元数x、y和z，x为1-1000的整数，y和z为0-1000的整数，x、y和z三者之和为3-1000。
在式IA和IB结合物的一个优选实施方案中，x和y为5-500，z为0-4。在一个特别优选的实施方案中，所用的二醇是一个二醇混合物，其中x为10-100，y为1-10，z为0。最优选的是式IA的干扰素结合物，其中m为1，R、R2和R4为CH3；R1为H；x大约为19，y大约为2，z为0。这对应于PEG单元的平均分子量约为1000道尔顿。
为了避免有关PEG分子中单元数的任何疑问，聚乙二醇聚合物用分子量表征优于指出PEG聚合物中用x、y和z来表示的自重复单元(SRU)数。这些数值由于起始PEG化合物的潜在不均一性而可能难于估计，因为这些起始PEG化合物通常由平均分子量定义而不是由它们所含的自重复单元数定义。不同分子量的起始PEG化合物可由本领域已知的方法制得或由供应商处购得。
假如由分子量测定得到的或由供应商标示的x、y和z值不是整数(一般是这种情况)，它们的值则必须按常用方法取舍而化为整数，从而使可能构成聚合物混合物的主要部分的聚合物分子中的上述数值为整数。
式IIA、IIB或III中的任何一个试剂同含一个以上游离氨基的IFN反应时，可能得到IFN同PEG试剂混合物的不同反应产物的混合物。这些反应产物是由于PEG试剂同一个或更多个游离氨基反应而形成的。这可由式IA和IB中的m表示。例如，当IFN含有三个游离氨基时，活化的PEG试剂可同其中的一个、二个或所有三个游离氨基反应。这种情形下，混合物包含所有三种情况下所形成的结合反应产物。由于这个混合物中的不同结合反应产物依m值的不同(即1、2或3)而具有大不相同的分子量，这些反应产物可用传统方法(如色谱法)分离。为确定m以及x、y和z是否选取适当，分离的结合反应产物可用与筛选IFN母体同样的方法筛选有生物活性的结合反应产物，从而确定结合反应产物是否仍保持了用未形成结合物的IFN的一部分生物活性。
按照优选的实施方案，m为1。即使有两个或更多个游离氨基也能得到m为1的结合物。活化的PEG试剂首先同IFN中包含的游离氨基之一发生反应。通过控制试剂(如IFN)的浓度和反应条件，按照胺缩合的标准方法，可控制蛋白质中包含的游离氨基的聚乙二醇化程度。在包含一个或更多个游离氨基的蛋白质中，若有一个游离氨基较其它氨基活泼，可选择反应条件使蛋白质同活化的PEG化合物反应以形成m为1的式IA或IB化合物。形成蛋白质的氨基酸中所含的其它游离氨基可通过延长缩合反应时间或利用其它更剧烈的反应条件进一步同PEG反应。
本说明书和权利要求书中所用的术语干扰素和IFN包括所有类型的干扰素(即：具有干扰素活性的分子)，例如，α、β、γ和ω干扰素以及这些类型的所有亚类，如α1、α2、α2A、α2B或α2C以及不同类型和/或亚类干扰素的杂种分子或嵌合体。干扰素可以是任何来源的，可以从天然来源、组织培养或由重组DNA技术得到。制备或分离天然或重组干扰素的方法在本领域中是公知的，并在如下公开号的专利申请中有所描述：EP43980、EP211148、EP140127、DE3028919、USP4503035和USP4414150。
使用R1、R2、R3和R4中至少有一个为低级烷基尤其是甲基的式IIA、IIB和III的试剂(烷基取代试剂)，其优点在于当用烷基取代试剂时，同相应的非取代试剂相比可以出人意料地提高结合物即PEG化蛋白质的产率。在相同反应时间内，烷基取代试剂同相应的非取代试剂相比，制备结合物时，前者可得到至少两倍量的结合物。
当给予病人由上述的取代试剂制备的式IA和IB结合物用于治疗时，这些结合物同由相应的非取代试剂制备的结合物相比，在病人血流中的体内半寿期意外地提高。虽然体内半寿期同结合物的分子量成正比，由取人试剂制得的结合物出人意料地同由非取代试剂制得的较高分子量的结合物具有同样长的半寿期。治疗剂在病人血流中的半寿期较长能提高对病人给药的效率。例如，由烷基取代试剂制得的结合物可以比由相应的非取代试剂制得的结合物给药次数少，或者用量较少。为了提高同聚乙二醇结合的生物性蛋白质的给药效率，形成这些蛋白质结合物时使用了较高分子量的聚乙二醇。然而，结合的活性IFN的生物效能随分子量增大而减小。但是，通过使用本发明的由取代试剂制得的结合物，相对于使用相应的非取代结合物提高了给药效率，但分子量增加较少。
在另外一个实施方案中，本发明也涉及制备新型结合物的方法。
式IA的结合物可如下制备：其中，R、R1、R2、R3、R4和R5，m和x、y和z同上；附带条件是R1、R2、R3、R4中任何一个或更多个都可以是低级烷基。
在这一反应中，PEG-胺在烃或氯代烃熔剂中同式IV化合物混合以制备式IIA化合物。式IIA化合物可在水性介质中同蛋白质的一个或更多个游离氨基缩合以制备式IA的结合物。这个反应可在水性介质中胺缩合的常规条件下进行。该反应通常在pH7-10的标准缓冲水溶液中进行，以制备式IA的结合物。依蛋白质中的游离氨基数和反应时间而定，该反应可制备不同分子量的PEG蛋白质结合物的混合物。PEG蛋白质结合物接下来可用常规方法如高效液相色谱(HPLC)或凝胶电泳法分出各个组分。用HPLC或凝胶电泳法依分子量来分离化合物的任何常规方法均可使用。这个混合物的分离可按照本文所述的所得产物的分子量来进行。
式IB的IFN结合物可按下列反应路线来制备：
Figure A9710543400111
其中，R、R1、R2、R3、R4、R5、m、x、y、z和附带条件如上所述。
式IV化合物由光气和2-羟基吡啶(当R5为低级烷基时为取代的2-羟基吡啶)用酰卤和醇缩合的任何常规方法制备。
PEG醇同式IV化合物的缩合利用醇和碳酸酯缩合的常规条件进行以制备式IIB化合物。式IIB化合物通过蛋白质上的一个或更多个游离氨基同蛋白质缩合，以制备式IB化合物。该反应可按照上述的式IIA化合物缩合制备式IA结合物的方法进行。依蛋白质中与式IIB化合物发生反应的游离氨基数的不同，式IB的结合物可由不同分子量结合物的混合物组成。该结合物混合物可用前面描述过的方法来分离。
式IB化合物也可用如下反应路线来制备：
Figure A9710543400131
其中，R、R1、R2、R3、R4、R5、m、x和y均如上所述。
在该反应路线中，PEG-醇同式IV化合物缩合以制备式III化合物。在该反应中，式IIB化合物作为中间产物形成之后与另一摩尔的PEG-醇反应生成式III化合物。在该反应进行时，PEG-醇的用量至少为每摩尔式IV化合物用2摩尔PEG-醇。在这一步骤中，醇同碳酸酯缩合的任何常规方法均可使用。式III化合物同干扰素反应形成式IB结合物是按照上述的式IIA化合物转化为式IA化合物的方法进行的。依蛋白质所含的游离氨基数，式III化合物同蛋白质缩合得到各种结合物的混合物，该混合物可用前面描述的分离IA结合物的方法分离成各个组分。
按照本发明，已发现本发明的干扰素结合物同用于形成结合物的蛋白质具有同样的效用。这样，这些结合物同形成它们的蛋白质具有相同形式的治疗活性，可以按与蛋白质本身相同的方式使用，而不会产生在给予病人蛋白质本身时可能引起的不良免疫反应。因此，本发明也包括以式I化合物或其盐为主要成分的药物组合物以及制备这些组合物的方法。
本发明用来控制或预防疾病的药物组合物包括通式I的干扰素结合物和治疗惰性的、治疗上可接受的无毒的载体物质。欲使用的药物组合物可制成制剂，并按与合适的医疗惯例一致的方式给药，并应考虑所要治疗的疾病、病人的个体状况、蛋白质结合物的释放部位、给药方法以及操作者已知的其它因素。
下述实施例代表本发明的说明性实施方案，但本发明不受这些实施例的限制。
在这些实施例中所用的Jeffamine M-2070是由环氧丙烷和环氧乙烷衍生而来的、平均分子量为2070的单甲氧基聚氧化烯丙胺聚合物，其骨架由聚乙二醇组成，并平均包含30％无规结合的环氧丙烷基团。
Jeffamine M-1000是平均分子量为1000的单甲氧基聚氧化烯丙胺聚合物，它由环氧丙烷和环氧乙烷衍生而来，其骨架由聚乙二醇组成，并包含14％专一性结合的环氧丙烷基团，其中x平均为18.6，y平均为1.6，z为0(这里所用的x、y和z的意义如上所述)。
这些实施例中所用的所有试剂均在4℃下于棕色瓶中干燥贮存备用。每次修饰反应都使用新鲜的等分试剂。
                     实施例
                     实施例1
α，α′-氧亚甲基双[ω-甲氧基聚(氧-1，2-亚乙基)]SRU111的制备
从含1.5克MPEG(甲氧基聚乙二醇，分子量为5000)的80ml干燥甲苯的悬浮液中蒸去50ml溶剂。溶液冷却后加入30.5mg碳酸二-2-吡啶酯。然后将得到的混合物回流24小时。将溶液冷却，得到的沉淀过滤后，先用少量甲苯洗涤，再用乙醚洗涤，得到的固体在高真空下干燥得到0.6克α，α′-氧亚甲基双[ω-甲氧基聚(氧-1，2-亚乙基)]SRU111白色粉末。经PEG修饰的干扰素由下述的方法1制备。
经PEG修饰的干扰素-α的制备
方法1：浓度为每ml 5g蛋白质的重组干扰素-α在含5mM乙酸钠(pH 5.0)、120mMNaCl的缓冲液中渗析。加入硫氰酸钾达最后浓度为0.5M，加入1/10体积pH11.9的1M Tricine-氢氧化钠调节pH值，得到最终pH为10.0的溶液。PEG试剂以固体或DMSO溶液(DMSO的体积小于总体积的10％)形式按3∶1摩尔比加入到蛋白质中。在室温下进行修饰反应30分钟到4小时，然后加入1ML-甘氨酸(pH6.3)到最后浓度为20mM以终止进一步的修饰。加入3.5M硫酸铵、50mM磷酸钠，pH7.0，使硫酸铵的最后浓度达到1.1M(对于PEG-1000为1.0M硫酸铵)，使经PEG修饰的蛋白质沉淀，沉淀经离心收集，洗涤后再溶于pH5.0的25mM乙酸铵中。经PEG修饰的蛋白质在疏水交换柱(如75×7.5mm)如BioRad TSK Pheny1-5-PW或ToyopearlPheny1-650M上用色谱法纯化，使用pH7.0的50mM磷酸钠溶液中硫酸铵浓度递减的梯度。另一种方法是，PEG-IFN在用25mM乙酸钠(pH5.0)、200mM NaCl平衡的Sephacryl S-200.柱(如90cm×3.2cm柱)(Pharmacia)上进行凝胶过滤纯化。经PEG修饰的蛋白质用SDS-PAGE鉴定。从柱中洗脱出相应于结合有一个PEG(PEG1-IFN)或两个PEG(PEG2-IFN)的IFN的蛋白质，合并这些蛋白质并浓缩后，通过测定280nm处的光吸收或用比色分析法(Pierce)测定蛋白质浓度。PEG-IFN在4℃下于含50mM磷酸钠(pH7.0)、0.3M硫酸铵的缓冲液中贮存。
方法2：大约6mg/ml蛋白质浓度的干扰素α-2a用5mM乙酸钠(pH 5.0)、0.12M氯化钠渗析。以1.0mg-1 ML为消光系数测定280nm处的光吸收，以此来测定蛋白质浓度。蛋白质溶液以蛋白质：试剂为1∶3的摩尔比与修饰试剂混合。用1/10体积的pH10.7的0.1MNa2B4O7-NaOH调节pH到10.0，从而引发修饰反应。在室温下保温1小时后，通过加入1/20体积pH7.5的1M甘氨酸终止反应。3-5分钟后，加入1/20体积的pH4.0的1M乙酸钠使pH降至5.0-6.0。
含PEG-干扰素、已停止反应的试剂和未修饰干扰素的溶液用pH4.5的40mM乙酸铵稀释4倍后，移至一个羧甲基纤维素柱(Whatman CM-52，每mg蛋白质约0.5ml树脂)上，用5倍体积pH4.5的40mM乙酸铵洗柱后，PEG-干扰素和未修饰干扰素用氯化钠在pH4.5的40mM乙酸铵中的线性梯度(0-0.5M)洗脱，含蛋白质的级分用280nm处的光吸收来鉴定，含PEG-干扰素的级分由SDS-PAGE来鉴定。
PEG-干扰素在装有Sephacryl S-200树脂(Pharmacia LKB)的柱上用排阻-凝胶过滤色谱法进一步纯化。从柱中洗脱出的级分用SDS-PAGE来分析，合并含PEG-干扰素的峰物质。
                 实施例2
α，α-氧亚甲基双[ω-甲氧基聚(氧-1，2-亚乙基)]SRU28.3的制备
按实施例1中描述的方法，将MPEG(分子量1300)转化为α，α-氧亚甲基双[ω-甲氧基聚(氧-1，2-亚乙基)SRU28.3，经PEG修饰的干扰素用这个试剂按实施例1中所述方法1来制备。
                 实施例3
α-甲基-ω-[2-[[2-吡啶基氧)羰基]氧]乙氧基]-聚(氧-1，2-亚乙基)SRU111.7的制备
从含1克分子量为5000的MPEG的30ml干燥CH2Cl2溶液中蒸出10ml溶剂。溶液冷却到室温后加入132mg(0.6mM)碳酸-2-吡啶酯和4mg DMAP。得到的溶液搅拌14小时后真空下除去溶剂。残余物用乙醚研制并将得到的沉淀过滤。然后将产物溶于7ml干燥的甘醇二甲醚中，加热使其溶解，使得到的溶液冷却，并在室温下放置数小时。然后将得到的沉淀过滤并用2×5ml干燥的甘醇二甲醚洗涤，固体在氮气流下于真空炉中干燥，得到0.7克α-[(2-吡啶基氧)羰基]-ω-甲氧基聚(氧-1，2-亚乙基)SRU111.7。
元素分析  C9H11NO4(CH2CH2O)111.7的计算值：C，54.57；H，9.02；N，0.28。实测值：C，54.51；H，9.19；N，0.28。
经PEG修饰的干扰素用这个试剂按实施例1中所述方法1来制备。
               实施例4
α-[(2-吡啶基氧)羰基]-ω-甲氧基聚(氧-1，2-亚乙基)SRU225的制备
分子量为10,000的MPEG按实施例3中所述方法转化为α-[(2-吡啶基氧)羰基]-ω-甲氧基聚(氧-1，2-亚乙基)SRU225。
元素分析  C9H11NO4(CH2CH2O)225的计算值：C，54.54；H，9.08；N，0.14。实测值：C，54.54；H，9.12；N，0.11。
经PEG修饰的干扰素用这个试剂按实施例1中所述方法1来制备。
                     实施例5
α-甲基-ω-[2-[2-[[(2-吡啶基氧)羰基]氧]丙氧基]丙氧基]聚(氧-1，2-亚乙基)SRU64.7的制备
从含0.5克α-2-[2-(羟基丙氧基)丙基]-ω-甲氧基聚(氧-1，2-亚乙基)SRU64.7的40ml干燥CH2Cl2溶液中蒸去15ml溶剂。然后向溶液中加入108mg碳酸二-2-吡啶酯、4mg DMAP和几粒4A分子筛。混合物搅拌过夜，过滤后减压除去溶剂。残余物通过排阻色谱法纯化。
这个试剂对应于式IIB-1化合物：其中n约为64，这相当于聚合物的分子量约为3000道尔顿。
经PEG修饰的干扰素用这个试剂按实施例1中所述方法1来制备。
                    实施例6
α-甲基-ω-[2[2-[[(2-吡啶基氧)羰基]氧]丙氧基]丙氧基]聚(氧-1，2-亚乙基)SRU110的制备
α-2-[2-(羟基丙氧基)丙基]-ω-甲氧基聚(氧-1，2-亚乙基)SRU110按实施例5中所述方法转化为α-甲基-ω-[2-[2-[[(2-吡啶基氧)羰基]氧]丙氧基]丙氧基]聚(氧-1，2-亚乙基)SRU110。
这个试剂(IIB-2)除了n大约为110，对应于5000道尔顿外，同实施例5所述的化合物(IIB-1)相当。
经PEG修饰的干扰素用这个试剂按实施例1中所述方法1来制备。
实施例7
甲基环氧乙烷同环氧乙烷的聚合物2-[[(2-吡啶基氧)羰基]氨基]丙基甲基醚(MO/O＝10/32)的制备
从含1克Jeffamine M-2070(Texaco Chemical Co.)的40ml干燥CH2Cl2溶液中蒸出15ml溶剂。溶液冷却到0℃并加入215mg碳酸二-2-吡啶酯。得到的溶液在0℃下再搅拌4小时，之后减压除去溶剂。残余物用串连的两个Phenomenex排阻色谱柱(500和1000)纯化。该产物在紫外光谱上显示232nm和310nm两个吸收带。
这个试剂对应于下式化合物：
Figure A9710543400191
其中，R5为H，R2为H或甲基，并且，作为平均分布，当R2为H时n为32，当R2为甲基时n为10。
经PEG修饰的干扰素用这个试剂按实施例1中所述方法2来制备。
                      实施例8
甲基环氧乙烷同环氧乙烷的聚合物2-[[(3-甲基-2-吡啶基氧)羰基]氨基]丙基甲基醚(MO/O＝10/32)的制备
按实施例7中所述方法，1克Jeffamine M-2070同碳酸双(3-甲基-2-吡啶基)酯反应得到甲基环氧乙烷同环氧乙烷的聚合物2-[[(3-甲基-2-吡啶基氧)羰基]氨基]丙基甲基醚(MO/O＝10/32)。
除了R5为CH3外，这个试剂(IIA-2)同实施例7中所述化合物(IIA-1)相当。
经PEG修饰的干扰素用这个试剂按实施例1中所述方法1来制备。
                        实施例9
甲基环氧乙烷同环氧乙烷的聚合物2-[[(2-吡啶基氧)羰基]氨基]丙基甲基醚嵌段(MO/O＝1.6/18.6)的制备
按实施例7中所述方法，0.6克Jeffamine M-1000(TexacoChemical Co.)同155.6mg碳酸二-2-吡啶酯反应得到甲基环氧乙烷同环氧乙烷的聚合物-[[(2-吡啶基氧)羰基]氨基]丙基甲基醚嵌段(MO/O＝1.6/18.6)。
得到下式化合物：
Figure A9710543400201
其中聚合物中各单元的平均分布如所示。
经PEG修饰的干扰素用该试剂按实施例1中所述方法1来制备。
干扰素的抗病毒活性：对干扰素及经PEG修饰的干扰素的抗病毒活性进行了测定(Rubenstein等人，(1981)J.Virol.37：755-758；Familletti等人，(1981)Methocls Enzymol.78：387-394)。所有的测定都相对于对照物进行了标准化。测定中所用的干扰素标准物的比活性为每mg蛋白质2×108单位。
修饰干扰素所用条件是以所述的最优化程序为基础的。PEG修饰过程中，由SDS-PAGE分析不同培养时间内干扰素转化为单PEG-干扰素的转化率(化学反应性)以及不同种类PEG-干扰素结合物的分布(位点选择性)。在SDS-PAGE中，观察到经PEG修饰的物质是凝胶上的迁移较慢的条带。单PEG-干扰素和双PEG-干扰素的产率都足以使它们能够用疏水性相互作用色谱法从反应混合物中纯化出来。测定纯化的PEG-干扰素的抗病毒活性并与未修饰的干扰素-α2a标准物比较。所用聚合物的分子量以及一些PEG化的衍生物的抗病毒活性如表1所示。
                表1PEG试剂的物理性质及其蛋白质结合物的生物活性
                                抗病毒活性实施例化合物                        (％对照物)
          聚合物分子量   单PEG    双PEG
4           10000          25       2
3            5000          40       4
1            5000          40       ND
6            5000          40       ND
5            3000          60       ND
7            2070          45       ND
2            1300          70       ND
9            1000         100       40ND＝未测

Claims (4)

1.一种具有下式的化合物：其中R为低级烷基；R1、R2、R3和R4为H或甲基；x为1-1000的整数，y和z为0-1000的整数，x、y和z三者之和为3-1000。
2.权利要求1的化合物，其中选择x、y和z，使得所述化合物的分子量在大约300-30000道尔顿的范围内。
3.权利要求1的化合物，其中R1、R2、R3和R4中至少有一个为低级烷基。
4.权利要求1的化合物，其中R为甲基。
CNB971054347A 1992-08-26 1997-05-23 聚乙二醇-干扰素结合物 Expired - Lifetime CN1155618C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US935770 1992-08-26
US935,770 1992-08-26
US07/935,770 US5382657A (en) 1992-08-26 1992-08-26 Peg-interferon conjugates

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN93116479A Division CN1039015C (zh) 1992-08-26 1993-08-25 聚乙二醇-干扰素结合物

Publications (2)

Publication Number Publication Date
CN1173500A true CN1173500A (zh) 1998-02-18
CN1155618C CN1155618C (zh) 2004-06-30

Family

ID=25467637

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB971054339A Expired - Lifetime CN1183112C (zh) 1992-08-26 1993-08-25 聚乙二醇-干扰素结合物
CN93116479A Expired - Lifetime CN1039015C (zh) 1992-08-26 1993-08-25 聚乙二醇-干扰素结合物
CNB971054347A Expired - Lifetime CN1155618C (zh) 1992-08-26 1997-05-23 聚乙二醇-干扰素结合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CNB971054339A Expired - Lifetime CN1183112C (zh) 1992-08-26 1993-08-25 聚乙二醇-干扰素结合物
CN93116479A Expired - Lifetime CN1039015C (zh) 1992-08-26 1993-08-25 聚乙二醇-干扰素结合物

Country Status (37)

Country Link
US (1) US5382657A (zh)
EP (1) EP0593868B1 (zh)
JP (1) JP2859105B2 (zh)
KR (1) KR100295520B1 (zh)
CN (3) CN1183112C (zh)
AT (1) ATE165102T1 (zh)
AU (1) AU668742B2 (zh)
BG (1) BG98067A (zh)
BR (1) BR9303469A (zh)
CA (1) CA2103829C (zh)
CZ (1) CZ169393A3 (zh)
DE (1) DE69317979T2 (zh)
DK (1) DK0593868T3 (zh)
EE (1) EE9400151A (zh)
ES (1) ES2116376T3 (zh)
FI (1) FI109765B (zh)
HR (1) HRP931094A2 (zh)
HU (1) HUT67013A (zh)
IL (1) IL106750A0 (zh)
IS (1) IS4067A (zh)
LT (1) LT3174B (zh)
LV (1) LV10907B (zh)
MW (1) MW7693A1 (zh)
MX (1) MX9305146A (zh)
MY (1) MY131445A (zh)
NO (1) NO933028D0 (zh)
NZ (2) NZ248452A (zh)
OA (1) OA09850A (zh)
PH (1) PH30460A (zh)
PL (1) PL300194A1 (zh)
RO (1) RO112730B1 (zh)
SI (1) SI9300423A (zh)
SK (1) SK89893A3 (zh)
UY (1) UY23635A1 (zh)
YU (1) YU56693A (zh)
ZA (1) ZA936098B (zh)
ZW (1) ZW11193A1 (zh)

Families Citing this family (288)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68925966T2 (de) * 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
EP0393438B1 (de) 1989-04-21 2005-02-16 Amgen Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5711944A (en) * 1993-11-10 1998-01-27 Enzon, Inc. Interferon polymer conjugates
PT726778E (pt) * 1994-02-08 2001-12-28 Amgen Inc Sistema de administracao oral de proteinas g-csf modificadas quimicamente
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
DE4435087A1 (de) * 1994-09-30 1996-04-04 Deutsches Krebsforsch Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
DE19514087A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
CA2329474C (en) 1995-11-02 2002-02-26 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
CA2302834A1 (en) * 1997-09-18 1999-03-25 F. Hoffmann-La Roche Ag Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
ID28470A (id) * 1998-03-26 2001-05-24 Schering Corp Formulasi-formulasi untuk perlindungan terhadap konjugasi polietilen glikol-interferon alfa
DE69920002T2 (de) 1998-04-28 2005-09-22 Applied Research Systems Ars Holding N.V. Konjugate aus polyole und beta-interferon
KR100694345B1 (ko) 1998-05-15 2007-03-12 쉐링 코포레이션 리바비린 및 인터페론 알파를 포함하는, 만성 ｃ형 간염에 걸린 항-바이러스 치료에 대한 나이브 환자의 치료용 약제학적 조성물
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
CA2330611A1 (en) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
ES2251196T3 (es) * 1998-06-08 2006-04-16 F. Hoffmann-La Roche Ag Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica.
US20030143662A1 (en) 1998-06-16 2003-07-31 Cummings Richard D. Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
DE69934890D1 (de) * 1998-06-16 2007-03-08 Univ Oklahoma Glykosulfopeptide und verfahren zu deren herstellung und deren verwendung
PT1121156E (pt) 1998-10-16 2006-05-31 Biogen Idec Inc Conjugados de polimeros de interferao-beta-1a e as suas utilizacoes
PT1121382E (pt) * 1998-10-16 2006-10-31 Biogen Idec Inc Proteinas de fusao do interferao beta e as respectivas utilizacoes
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL144259A0 (en) 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
KR100689212B1 (ko) * 1999-01-29 2007-03-09 암겐 인코포레이티드 Ｇｃｓｆ 결합체
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
DE60045591D1 (de) 1999-04-08 2011-03-10 Schering Corp Melanomtherapie
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
JP4737903B2 (ja) 1999-07-07 2011-08-03 ザイモジェネティクス， インコーポレイテッド ヒトサイトカイン受容体
AU4934299A (en) * 1999-07-15 2001-02-05 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) * 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
CA2387205A1 (en) 1999-10-12 2001-04-19 Santen Pharmaceutical Co., Ltd. Interferon complex and pharmaceutical use thereof
KR20020065517A (ko) * 1999-11-12 2002-08-13 맥시겐 홀딩스 리미티드 인터페론 감마 접합체
YU32402A (sh) 1999-11-12 2005-03-15 Maxygen Holdings Ltd. Konjugati gama interferona
AU2044001A (en) 1999-11-19 2001-05-30 Board Of Trustees Of The Leland Stanford Junior University Targeted bifunctional molecules and therapies based thereon
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
US6887842B1 (en) * 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
JP2003534773A (ja) 1999-12-03 2003-11-25 ザイモジェネティクス，インコーポレイティド ヒトサイトカイン受容体
DE60139110D1 (de) 2000-01-10 2009-08-13 Maxygen Holdings Ltd G-csf konjugate
AU2001232951A1 (en) * 2000-01-24 2001-07-31 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
DK1257295T3 (da) 2000-02-11 2009-08-10 Bayer Healthcare Llc Faktor VII eller VIIA-lignende molekyler
KR100353392B1 (ko) * 2000-03-13 2002-09-18 선바이오(주) 높은 생체 활성도를 갖는 생체 활성 단백질과 ｐｅｇ의결합체 제조방법
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
WO2002032957A1 (fr) * 2000-10-16 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Erythropoietine modifiee par peg
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
AU2002230659A1 (en) 2000-11-07 2002-05-21 Zymogenetics Inc. Human tumor necrosis factor receptor
JP2004532289A (ja) * 2001-02-20 2004-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 末端分枝高分子リンカーおよびそれを含む高分子複合体
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
DE60232434D1 (de) 2001-02-27 2009-07-09 Maxygen Aps Neue interferon-beta-ähnliche moleküle
US6875845B2 (en) 2001-03-02 2005-04-05 Zymogenetics, Inc. Mouse cytokine receptor
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
WO2002083166A1 (fr) * 2001-04-10 2002-10-24 Santen Pharmaceutical Co., Ltd. Complexes de polymeres d'interferons et leur utilisation medicinale
CA2448123C (en) 2001-05-24 2012-09-11 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins
WO2003000278A1 (fr) * 2001-06-22 2003-01-03 Kyowa Hakko Kogyo Co., Ltd. Onguents
MD2053C2 (ro) * 2001-07-10 2003-07-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Remediu cu acţiune interferonogenă
CA2457876C (en) 2001-08-22 2011-10-11 Bioartificial Gel Technologies Inc. Process for the preparation of activated polyethylene glycols
US20050095224A1 (en) * 2001-12-07 2005-05-05 Ramachandran Radhakrishnan Compositions and method for treating hepatitis virus infection
KR100888371B1 (ko) 2002-01-17 2009-03-13 동아제약주식회사 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
RS55578B1 (sr) * 2002-01-18 2017-06-30 Biogen Ma Inc Polimerna jedinjenja polialkilena i njihova upotreba
WO2003076490A1 (fr) * 2002-03-13 2003-09-18 Beijing Jiankai Technology Co., Ltd. Derive polymere hydrophile a ramification de type y et procede de preparation d'un composite medical contenant le compose precite
WO2003087308A2 (en) * 2002-04-11 2003-10-23 Zymogenetics, Inc. Use of interleukin-24 to treat ovarian cancer
WO2003089603A2 (en) 2002-04-19 2003-10-30 Zymogenetics, Inc. Cytokine receptor
PL211175B1 (pl) 2002-06-21 2012-04-30 Novo Nordisk Healthcare Ag Koniugat polipeptydu czynnika VII, sposób wytwarzania takiego koniugatu, zawierający taki koniugat preparat farmaceutyczny oraz zastosowanie takiego koniugatu
WO2004005341A2 (en) * 2002-07-03 2004-01-15 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
WO2004012773A1 (en) 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
KR20050083678A (ko) * 2002-09-05 2005-08-26 더 제너럴 하스피탈 코포레이션 아시알로-인터페론과 간암의 치료
CA2497777A1 (en) * 2002-09-05 2004-03-18 The General Hospital Corporation Modified asialo-interferons and uses thereof
ES2285215T3 (es) * 2002-09-27 2007-11-16 F. Hoffmann-La Roche Ag Conjugados de la proteina de fijacion del factor de crecimiento de tipo insulina 4 y poli(etilenglicol).
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
NZ541124A (en) * 2002-12-26 2008-08-29 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
CA2511815A1 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
CN1744918A (zh) * 2002-12-31 2006-03-08 尼克塔治疗亚拉巴马公司 含有酮或相关官能团的聚合物试剂
JP2006517995A (ja) * 2003-02-19 2006-08-03 ファルマシア・コーポレーション 活性化されたポリエチレングリコールエステル類
WO2004076474A2 (en) * 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
US20070077225A1 (en) * 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
EP1668031B1 (en) 2003-08-07 2008-03-12 ZymoGenetics, Inc. Homogeneous preparations of il-29
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
WO2005035565A1 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
CA2540858C (en) 2003-10-14 2009-12-08 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
WO2005042563A2 (en) * 2003-10-22 2005-05-12 Akzo Nobel N.V. Process for incrasing protein pegylation reaction yields by diafiltration ultrafiltration
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
WO2005062949A2 (en) * 2003-12-23 2005-07-14 Intermune, Inc. Method for treating hepatitis virus infection
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
WO2005074524A2 (en) * 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
AU2005319099B2 (en) * 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
WO2005113592A2 (en) * 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
KR101699142B1 (ko) * 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
EP1771573A4 (en) * 2004-07-21 2009-02-18 Ambrx Inc BIOSYNTHETIC POLYPEPTIDES OBTAINED FROM NON-NATURALLY CITED AMINO ACIDS
AU2005266892B2 (en) 2004-07-29 2011-03-03 Bristol-Myers Squibb Company Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
CA2576549C (en) 2004-08-12 2011-01-18 Schering Corporation Stable pegylated interferon formulation
EP2301963A1 (en) 2004-09-23 2011-03-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
JP4990792B2 (ja) * 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド アミノアシル−ｔＲＮＡシンテターゼの組成物およびこの使用
CN103290084A (zh) 2004-12-22 2013-09-11 Ambrx公司 表达和纯化重组人类生长激素的方法
MX2007007587A (es) * 2004-12-22 2007-12-11 Ambrx Inc Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural.
WO2006086396A2 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
US7619067B2 (en) * 2005-05-18 2009-11-17 Maxygen, Inc. Evolved interferon-alpha polypeptides
JP2008541769A (ja) * 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド 改善されたヒトインターフェロン分子及びそれらの使用
CA2611836A1 (en) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
KR20080033274A (ko) 2005-06-17 2008-04-16 노파르티스 아게 Ｈｃｖ에서 상글리페린의 용도
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
US7695710B2 (en) 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
JP2008543943A (ja) * 2005-06-20 2008-12-04 ペプゲン コーポレイション ヒトインターフェロンアルファ類似体とインターフェロンタウの低毒性長期循環性キメラ
CN101304758B (zh) * 2005-06-29 2013-08-21 维兹曼科学研究所耶达研究与发展有限公司 重组干扰素α2（IFNα2）突变体
NZ594105A (en) 2005-07-25 2013-02-22 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
MX2008002149A (es) * 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
AU2006294511B2 (en) 2005-09-28 2011-11-17 Zymogenetics, Inc IL-17A and IL-17F antagonists and methods of using the same
WO2007044893A2 (en) 2005-10-11 2007-04-19 Intermune, Inc. Compounds and methods for inhibiting hepatitis c viral replication
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
CN101291684A (zh) * 2005-10-21 2008-10-22 阿维季尼克斯股份有限公司 甘醇化和糖基化的禽类来源的治疗性蛋白
RS51998B (en) * 2005-11-08 2012-04-30 Ambrx Inc. ACCELERATORS FOR MODIFICATION OF NON-NATURAL AMINO ACIDS AND NON-NATURAL AMINO ACID POLYPEPTIDES
CA2626522A1 (en) * 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
SG170116A1 (en) * 2005-12-14 2011-04-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP5046030B2 (ja) 2006-01-12 2012-10-10 北里第一三共ワクチン株式会社 インターフェロンαを含む口腔組成物
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
ES2543840T3 (es) 2006-04-11 2015-08-24 Novartis Ag Inhibidores espirocíclicos del VHC/VIH y sus usos
CA2653748A1 (en) * 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
CN101484576A (zh) 2006-05-24 2009-07-15 诺沃-诺迪斯克保健股份有限公司 具有延长的体内半寿期的因子ix类似物
JP5031827B2 (ja) 2006-06-01 2012-09-26 程云 予防或いは肝損傷を治療するペプチッド
CN1911447B (zh) * 2006-06-30 2010-05-12 复旦大学 转铁蛋白-聚乙二醇-药物分子复合物及其制备药物的用途
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP2054076A2 (en) * 2006-08-21 2009-05-06 United Therapeutics Corporation Combination therapy for treatment of viral infections
CN101511856B (zh) * 2006-09-08 2016-01-20 Ambrx公司 脊椎动物细胞中抑制因子trna的转录
JP5399906B2 (ja) * 2006-09-08 2014-01-29 アンブルックス，インコーポレイテッド 脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
KR20090110295A (ko) 2006-11-22 2009-10-21 에드넥서스, 어 브리스톨-마이어스 스퀴브 알＆디 컴파니 Ｉｇｆ-ｉｒ을 포함하는 티로신 키나제 수용체에 대한 공학처리된 단백질에 기반한 표적화 치료제
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
AU2008247815B2 (en) * 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
KR101502645B1 (ko) * 2007-09-04 2015-03-13 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ｂ, 이의 제조 방법 및 용도
PT2196475E (pt) * 2007-09-04 2012-09-07 Biosteed Gene Expression Tech Co Ltd Interferão alfa-2a modificado por polietilenoglicol, seu processo de síntese e aplicação
CA2697992C (en) 2007-10-04 2017-08-22 Zymogenetics, Inc. B7 family member zb7h6 and related compositions and methods
CN101918579A (zh) 2007-10-22 2010-12-15 先灵公司 完全人抗-vegf抗体和使用方法
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
ME03057B (me) 2007-12-07 2019-01-20 Zymogenetics Inc Molekuli humanizovanih antitela specifični za il-31
NZ620606A (en) 2008-02-08 2015-08-28 Ambrx Inc Modified leptin polypeptides and their uses
EP2272875B1 (en) 2008-04-03 2014-01-15 Biosteed Gene Expression Tech. CO., LTD. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
WO2009158696A1 (en) 2008-06-27 2009-12-30 Zymogenetics, Inc. SOLUBLE HYBRID Fcγ RECEPTORS AND RELATED METHODS
PE20110426A1 (es) 2008-07-23 2011-07-01 Ambrx Inc Polipeptidos g-csf bovinos modificados
CN102224238B (zh) 2008-09-26 2015-06-10 Ambrx公司 非天然氨基酸复制依赖性微生物和疫苗
CN107022020A (zh) 2008-09-26 2017-08-08 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8834885B2 (en) 2009-06-04 2014-09-16 Novartis Ag Methods for identification of sites for IgG conjugation
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
CA2784800A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
JP2013528374A (ja) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Ｖｌａ４のポリペプチド阻害剤
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
WO2011159930A2 (en) 2010-06-16 2011-12-22 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
EP2585065A1 (en) 2010-06-24 2013-05-01 Panmed Ltd. Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
EP2595632A1 (en) 2010-07-23 2013-05-29 DemeRx, Inc. Noribogaine compositions
RS59193B1 (sr) 2010-08-17 2019-10-31 Ambrx Inc Modifikovani polipeptidi relaksina i njihova primena
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CA2811700A1 (en) 2010-10-05 2012-04-12 Novartis Ag New treatments of hepatitis c virus infection
EP2624826B1 (en) 2010-10-08 2018-07-18 Novartis AG Vitamin e formulations of sulfamide ns3 inhibitors
BR112013013166A2 (pt) 2010-11-30 2016-09-06 Novartis Ag tratamentos da infecção pelo vírus da hepatite c
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
AU2012233644A1 (en) 2011-03-31 2013-09-12 Novartis Ag Alisporivir to treat Hepatitis C virus infection
EP3006037A1 (en) 2011-04-01 2016-04-13 Novartis AG Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases
SG193908A1 (en) 2011-04-13 2013-11-29 Novartis Ag Treatment of hepatitis c virus infection with alisporivir
EP2709669A1 (en) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
US9422338B2 (en) 2011-05-19 2016-08-23 Epodose Llc Compounds that bind to the erythropoietin receptor
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
US20140314713A1 (en) 2011-07-20 2014-10-23 Universite Paris Diderot - Paris Vii Methods for determining treatment response in patients infected with hcv genotype 4
WO2013028233A1 (en) * 2011-08-25 2013-02-28 Nanogen Pharmaceutical Biotechnology Peg-interferon lambda 1 conjugates
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
CA2850052A1 (en) 2011-09-27 2013-04-04 Novartis Ag Alisporivr for treatment of hepatis c virus infection
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
AU2012347785B2 (en) 2011-12-06 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating viral diseases
CA2855994A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
US8454947B1 (en) 2012-03-01 2013-06-04 Nanogen Pharmaceutical Biotechnology PEG-interferon lambda 1 conjugates
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
EP2830663B1 (en) 2012-03-30 2019-02-06 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2013174988A1 (en) 2012-05-24 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and monitoring treatment response in hcv- and hcv/hiv-infected subjects
KR102163408B1 (ko) 2012-05-31 2020-10-08 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
CA2875989A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
CN109503714A (zh) 2012-06-21 2019-03-22 索伦托治疗有限公司 与c-Met结合的抗原结合蛋白
CN105051065A (zh) 2012-06-22 2015-11-11 索伦托治疗有限公司 与ccr2结合的抗原结合蛋白
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
HUE045227T2 (hu) 2012-08-31 2019-12-30 Sutro Biopharma Inc Azido csoportot tartalmazó módosított aminosavak
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
JP2016508979A (ja) 2012-12-20 2016-03-24 デメレックス， インコーポレイテッド 置換ノルイボガイン
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
LT3137078T (lt) 2014-05-01 2019-06-25 Eiger Biopharmaceuticals, Inc. Virusinio hepatito delta infekcijos gydymas
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CA2989550C (en) 2014-06-18 2023-08-08 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
EP3646879B1 (en) 2014-08-12 2024-04-03 Massachusetts Institute Of Technology Synergistic tumor treatment with integrin-binding-fc-fusion protein and an immune checkpoint inhibitor
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
WO2016028523A2 (en) 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr3
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
PT3412302T (pt) 2014-10-24 2021-06-09 Bristol Myers Squibb Co Polipéptidos de fgf-21 modificados e utilizações dos mesmos
EP4282485A3 (en) 2014-11-06 2024-01-17 PharmaEssentia Corporation Dosage regimen for pegylated interferon
JP6334810B2 (ja) * 2015-03-17 2018-05-30 国立大学法人信州大学 Ｉｆｎを用いた非接着培養による樹状細胞の調製方法
KR20220147695A (ko) 2015-04-21 2022-11-03 아이거 바이오파마슈티컬스 인코포레이티드 로나파르닙 및 리토나버를 포함하는 약제 조성물
BR112018009009A8 (pt) 2015-11-03 2019-02-26 Hoffmann La Roche terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
JP7187315B2 (ja) 2015-11-04 2022-12-12 アイガー・バイオファーマシューティカルズ・インコーポレイテッド デルタ型肝炎ウイルス感染の処置
CA3013051A1 (en) 2016-01-29 2017-08-03 Heyue Zhou Antigen binding proteins that bind pd-l1
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
AU2018207303A1 (en) 2017-01-10 2019-07-25 xCella Biosciences, Inc. Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
EP3570849A1 (en) 2017-01-18 2019-11-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
CN110637027A (zh) 2017-02-08 2019-12-31 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
EP3658173A1 (en) 2017-07-25 2020-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
WO2020032951A1 (en) 2018-08-09 2020-02-13 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
SG11202102427XA (en) 2018-09-11 2021-04-29 Ambrx Inc Interleukin-2 polypeptide conjugates and their uses
KR20210068478A (ko) 2018-09-28 2021-06-09 메사추세츠 인스티튜트 오브 테크놀로지 콜라겐-국재화된 면역조정성 분자 및 그의 방법
EP3867265A1 (en) 2018-10-19 2021-08-25 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
JP2022540699A (ja) 2019-07-18 2022-09-16 ウエヌイグレックオ・ファーマ インターフェロンの有害作用を減少させる方法
WO2021178612A1 (en) 2020-03-05 2021-09-10 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
EP3912627B1 (en) 2020-05-20 2022-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of coronavirus infections
US20210403908A1 (en) 2020-06-22 2021-12-30 Janssen Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis d virus infection
EP4199968A1 (en) 2020-08-20 2023-06-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
WO2022043496A2 (en) 2020-08-28 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mait cells as biomarkers and biotargets in covid-19
WO2022079205A1 (en) 2020-10-15 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ifn-alpha polypeptides for the treatment of coronavirus infections
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2651657A (en) * 1949-05-21 1953-09-08 Standard Oil Dev Co Synthetic lubricating oil
SE337223B (zh) * 1967-05-23 1971-08-02 Pharmacia Ab
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (zh) * 1967-12-20 1972-03-06 Pharmacia Ab
DK132327A (zh) * 1968-07-16
US3632828A (en) * 1968-12-16 1972-01-04 Dow Chemical Co Polyethylene glycol monomethyl ether carbonates
BE758425A (fr) * 1969-12-02 1971-04-16 Baxter Laboratories Inc Streptokinase liee chimiquement a une matrice en carbohydrate (
DE2247163A1 (de) * 1972-09-26 1974-03-28 Merck Patent Gmbh Traegermatrix zur fixierung biologisch wirksamer stoffe und verfahren zu ihrer herstellung
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
US4094744A (en) * 1976-11-18 1978-06-13 W. R. Grace & Co. Water-dispersible protein/polyurethane reaction product
EP0000938B1 (en) * 1977-08-22 1984-10-17 National Research Development Corporation Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
JPS55110105A (en) * 1979-02-19 1980-08-25 Japan Atom Energy Res Inst Preparation of polymer composition containing physiologically active material
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
US4486344A (en) * 1983-03-28 1984-12-04 Miles Laboratories, Inc. Urea-linked immunogens, antibodies, and preparative method
JPS6098988A (ja) * 1983-11-01 1985-06-01 Chemo Sero Therapeut Res Inst Ｌｐｆ−ｈａの精製法
JPS60127952A (ja) 1983-12-14 1985-07-08 Fanuc Ltd 領域加工方法
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1987000056A1 (en) * 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US4818769A (en) * 1985-09-20 1989-04-04 Cetus Corporation Method of controlling stress-related disease in livestock by administration of human IL-2
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4851220A (en) * 1986-11-26 1989-07-25 Schering Corporation Stable oleaginous gel
US4871538A (en) * 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
CA1308377C (en) * 1987-08-21 1992-10-06 Henry Berger, Jr. Complex of polyethyleneglycol and tissue plasminogen activator
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5199360A (en) 1988-09-27 1993-04-06 Sirkka Koistinen Table constructions
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
AU4660789A (en) * 1988-11-23 1990-06-12 Genentech Inc. Polypeptide derivatives
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
JP2875884B2 (ja) * 1989-04-19 1999-03-31 ノボ ノルディスク アクティーゼルスカブ ポリペプチドの修飾に使用するための活性ポリアルキレンオキシドカーボネート
ATE136315T1 (de) * 1989-05-27 1996-04-15 Sumitomo Pharma Verfahren für die herstellung von polyethylenglykolderivate und modifizierte proteine.
JP2978187B2 (ja) * 1989-11-02 1999-11-15 日本ケミカルリサーチ株式会社 修飾スーパーオキサイドディスムターゼの製造法
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
CA2067224C (en) * 1989-12-01 2001-02-13 Manfred Kurfuerst Hirudin/polyalkylene glycol conjugates
JPH04202293A (ja) * 1990-11-29 1992-07-23 Tonen Corp 作動油
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation

Also Published As

Publication number Publication date
CA2103829C (en) 2003-04-08
ATE165102T1 (de) 1998-05-15
NZ264872A (en) 1996-01-26
NO933028D0 (no) 1993-08-25
FI933740A0 (fi) 1993-08-25
YU56693A (sh) 1997-01-08
IL106750A0 (en) 1993-12-08
CN1088936A (zh) 1994-07-06
HUT67013A (en) 1995-01-30
KR100295520B1 (ko) 2001-09-17
FI109765B (fi) 2002-10-15
HRP931094A2 (en) 1997-06-30
ES2116376T3 (es) 1998-07-16
LV10907B (en) 1996-04-20
MW7693A1 (en) 1994-06-08
KR940003969A (ko) 1994-03-14
LV10907A (lv) 1995-12-20
CN1211578A (zh) 1999-03-24
JPH06192300A (ja) 1994-07-12
CZ169393A3 (en) 1994-04-13
BG98067A (en) 1994-12-02
NZ248452A (en) 1995-12-21
UY23635A1 (es) 1994-03-01
CN1183112C (zh) 2005-01-05
DK0593868T3 (da) 1999-02-08
LT3174B (en) 1995-02-27
DE69317979T2 (de) 1998-08-20
ZW11193A1 (en) 1994-03-23
EP0593868A1 (en) 1994-04-27
OA09850A (fr) 1994-08-15
JP2859105B2 (ja) 1999-02-17
CN1039015C (zh) 1998-07-08
IS4067A (is) 1994-02-27
SK89893A3 (en) 1994-04-06
ZA936098B (en) 1994-03-01
LTIP888A (lt) 1994-08-25
US5382657A (en) 1995-01-17
CA2103829A1 (en) 1994-02-27
BR9303469A (pt) 1994-03-22
AU4478093A (en) 1994-03-03
MY131445A (en) 2007-08-30
EE9400151A (et) 1996-02-15
PH30460A (en) 1997-05-28
SI9300423A (en) 1994-03-31
RO112730B1 (ro) 1997-12-30
HU9302366D0 (en) 1993-11-29
MX9305146A (es) 1994-03-31
CN1155618C (zh) 2004-06-30
PL300194A1 (en) 1994-04-05
FI933740A (fi) 1994-02-27
AU668742B2 (en) 1996-05-16
EP0593868B1 (en) 1998-04-15
DE69317979D1 (de) 1998-05-20

Similar Documents

Publication Publication Date Title
CN1039015C (zh) 聚乙二醇-干扰素结合物
CN1088721C (zh) 干扰素结合物
CN100335503C (zh) 多元醇干扰素β偶联物
CN1243779C (zh) 具有y形分支的亲水性聚合物衍生物、其制备方法、与药物分子的结合物以及包含该结合物的药物组合物
CN1309763C (zh) 喜树碱的高分子衍生物
RS63504A (en) Polyalkylene polymer compounds and uses thereof
CN1913925A (zh) 含有两组不同聚合物－活性剂缀合物的组合物
CN1800238A (zh) 有生物功能的脂肪族聚酯—聚氨基酸共聚物及合成方法
CN1020458C (zh) 偶联到高分子量的聚亚烷基二醇类上的超氧物歧化酶的结合物的制备方法
CN1260725A (zh) 包含叶酸拮抗物和载体的结合物
JP2009531478A (ja) 新規な活性化ポリ（エチレングリコール）及び関連ポリマー並びにそれらの適用
JPS6255079A (ja) 修飾ウリカ−ゼ
CN1611524A (zh) 聚乙二醇氨基酸n－内环羰酐活性衍生物及其药物键合物和凝胶
CA1247010A (en) Fibronectin-dextran-drug complex and method of preparation thereof
CN1375502A (zh) 聚乙二醇修饰重组人干扰素
CN1569892A (zh) 多臂树杈型聚乙二醇与蛋白质或多肽的结合物及其制备方法
CN1477126A (zh) 长效生长激素及药物组合物
CN1850278A (zh) 聚乙二醇修饰的重组人b淋巴细胞刺激因子及其制备方法
CN1124656A (zh) 协同多糖修饰的药用生物应答调节剂
CN1544472A (zh) 支链聚乙二醇－干扰素及其制法和用途

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20130825

Granted publication date: 20040630